Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June 2023.

Details are as follows:

Jefferies Global Healthcare Conference Location: New York, NYFormat: Presentation Date: Thursday, June 8Time: 2-2:25 PM ET Webcast Link: https://wsw.com/webcast/jeff281/cmpx/1864720

World Medical Innovation Forum hosted by Mass General Brigham Innovation and Bank of America Location: Boston, MA Format: Panel: The Disruptors: The Biologic Revolution in Cancer ContinuesDate: Tuesday, June 13Time: 8:30-9:30 AM ET

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.

About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact[email protected]

Media ContactAnna Gifford, Communications Manager[email protected] 617-500-8099

You May Also Be Interested In

• Recycling Council of Alberta recognizes Barry Friesen with Circular Champion Recognition Award
• Legacy Offer Releases Tacoma Home-Selling Guidance as Pierce County Listings Reach 55 Days on Market
• Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Can